Phase II trial of TS-1 and cisplatin in patients with Carcinoma of Unknown Primary Sites (KMOG 0607)

Phase II trial of TS-1 and cisplatin in patients with Carcinoma of Unknown Primary Sites (KMOG 0607) - Phase II trial of TS-1/Cisplatin in patients with CUPS (KMOG 0607)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001364

Enrollment

Registered

2008-09-09

Start date

2006-07-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma of Unknown Primary Sites

Interventions

Treatment: TS-1+CDDP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Histological confirmation of cancer (2)Cancer of unknown primary sites (3)Measureable disease (4)ECOG PS 0~2 (5)Adequate major organ function (6)All patients provided written informed consent.

Exclusion criteria

Exclusion criteria: (1)Massive pleural effusion or massive ascites (2)Symptomatic brain metastases

Design outcomes

Primary

Measure	Time frame
Response Rate	—

Secondary

Measure	Time frame
Safety, Overall survival, Progression free survival	—

Countries

Japan

Contacts

Public ContactHitoshi Kusaba

Kyushu University Hospital Division of Hematology and Oncology

hkusaba@intmed1.med.kyushu-u.ac.jp092-642-5232

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026